Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility.
about
Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression.Regenerative therapies in electrophysiology and pacing.Gene therapy for cardiac arrhythmias.Innovative approaches to anti-arrhythmic drug therapy.Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation.Experimental molecular and stem cell therapies in cardiac electrophysiology.Synergistic effects of inward rectifier (I) and pacemaker (I) currents on the induction of bioengineered cardiac automaticity.Regenerative therapies in electrophysiology and pacing: introducing the next steps.Mechanistic role of I(f) revealed by induction of ventricular automaticity by somatic gene transfer of gating-engineered pacemaker (HCN) channels.Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector.Gene therapy in cardiac arrhythmias.The effects of intracellular Ca2+ on cardiac K+ channel expression and activity: novel insights from genetically altered mice.Specific Cell (Re-)Programming: Approaches and Perspectives.Phospholamban as a crucial determinant of the inotropic response of human pluripotent stem cell-derived ventricular cardiomyocytes and engineered 3-dimensional tissue constructs.
P2860
Q34997952-91FBD7A9-D6AE-44DC-BE7E-C0AC6E1178C7Q35163143-7583A5F3-C68B-40AA-AF65-C65E4608AA95Q35807779-115B2D92-0F43-4154-A367-9070C4D7BF13Q36670460-35EB0E6F-02C3-4ACF-BCA8-93B74F2D4CC5Q36788875-7DEC2ECF-074E-488F-A560-C06E02E5331EQ37122811-1034C853-9BFF-42A2-83D6-9AAC611810BDQ37336156-054A54EE-2647-45A8-B2E4-6222A306243AQ37821376-97E5D79C-8004-4D1B-9497-F4D14FFFD689Q40153770-15B6987E-E15D-4261-A58F-7ABB83B7A628Q40703867-F8D9E744-F20B-4A52-94D2-10A65A5F8E15Q41466533-06F46A6D-583C-4743-A644-65D2FF39EE85Q46285770-BB5544ED-6A49-424F-9F9C-C25E2016BB60Q50085975-CA875744-49CB-48F7-80AA-3DEBD55327B2Q55036502-C122D525-9758-42EA-A60D-ACBB01284D92
P2860
Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Dual gene therapy with SERCA1 ...... out suppressing contractility.
@en
Dual gene therapy with SERCA1 ...... out suppressing contractility.
@nl
type
label
Dual gene therapy with SERCA1 ...... out suppressing contractility.
@en
Dual gene therapy with SERCA1 ...... out suppressing contractility.
@nl
prefLabel
Dual gene therapy with SERCA1 ...... out suppressing contractility.
@en
Dual gene therapy with SERCA1 ...... out suppressing contractility.
@nl
P2093
P2860
P356
P1476
Dual gene therapy with SERCA1 ...... out suppressing contractility.
@en
P2093
Anne M Murphy
Eduardo Marbán
H Bradley Nuss
Ronald A Li
P2860
P304
P356
10.1172/JCI0213359
P407
P577
2002-02-01T00:00:00Z